![Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1) - Annals of Oncology Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1) - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/0e2f4116-754f-442b-81bb-0ee95af48b07/gr1.jpg)
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1) - Annals of Oncology
![Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. - Abstract - Europe PMC Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6536994/bin/CAM4-8-1943-g001.jpg)
Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. - Abstract - Europe PMC
![Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/4c13ae9e-d374-45ea-8cc4-cc15231519b6/cam42095-fig-0001-m.jpg)
Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library
Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase | PLOS ONE
![EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2019-0370/asset/images/medium/figure1.gif)
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology
![Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY](https://touchoncology.com/wp-content/uploads/sites/2/2017/10/figure_1__mode_of_action_of_endocrine_theraples.png)
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
![Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | British Journal of Cancer Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.bjc.6601629/MediaObjects/41416_2004_Article_BF6601629_Fig3_HTML.jpg)
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | British Journal of Cancer
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer | Journal of Medicinal Chemistry
![Figure 2 from ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data | Semantic Scholar Figure 2 from ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fa0103655ba106ae8600571c39afd3b44f30e8d6/2-Figure2-1.png)
Figure 2 from ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data | Semantic Scholar
Understanding the estrogen receptor signaling pathway: focus on current endocrine agents for breast cancer in postmenopausal wom
![Mode of action of estradiol and fulvestrant. AF1: activation function... | Download Scientific Diagram Mode of action of estradiol and fulvestrant. AF1: activation function... | Download Scientific Diagram](https://www.researchgate.net/publication/260443189/figure/fig2/AS:267670947889155@1440829135938/Mode-of-action-of-estradiol-and-fulvestrant-AF1-activation-function-1-AF2-activation.png)
Mode of action of estradiol and fulvestrant. AF1: activation function... | Download Scientific Diagram
![IJMS | Free Full-Text | Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective IJMS | Free Full-Text | Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective](https://pub.mdpi-res.com/ijms/ijms-22-07812/article_deploy/html/images/ijms-22-07812-g001.png?1626933226)
IJMS | Free Full-Text | Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
![Estrogen alpha receptor antagonists for the treatment of breast cancer: a review | BMC Chemistry | Full Text Estrogen alpha receptor antagonists for the treatment of breast cancer: a review | BMC Chemistry | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13065-018-0472-8/MediaObjects/13065_2018_472_Fig1_HTML.png)
Estrogen alpha receptor antagonists for the treatment of breast cancer: a review | BMC Chemistry | Full Text
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives. - Document - Gale Academic OneFile
![Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1d28c7ec-ec64-4606-bda2-24bed6a800d4/cam42095-toc-0001-m.jpg?trick=1679142265841)